BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment-naïve and R/R CLL First results from Phase 1/2 sonrotoclax monotherapy study will demonstr
(Financial Post, 2025-11-20T11:09:02Z)